

| 카탈로그 번호 | DY286018 |
|---|---|
| 샘플 유형 | Plasma, Serum |
| 민감도 | 0.156 μg/ml |
| 범위 | 0.31-5 μg/mL |
| 등록번호 | P04626 |
| 응용 분야 | ELISA |
| 검출 방법 | Colorimetric |
| 분석 유형 | Quantitative |
| 회수율 | 80-120% |
| 배송 | 2-8 ℃ |
| 안정성 및 저장 | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
| 사양 | Disitamab |
| 대체 이름 | RC48-0, Disitamab Vedotin, 2185868-98-6 |
| 배경 | Receptor tyrosine-protein kinase erbB-2 (Disitamab) is a ~137 kDa protein. Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. |
| 참고 문헌 | 1. Deeks ED. Disitamab Vedotin: First Approval. Drugs. 2021;81(16):1929-1935. [DY286018] 2. Jiang J, et al. Preclinical safety profile of disitamab vedotin: a novel anti-HER2 antibody conjugated with MMAE. Toxicol Lett. 2020;324:30-37. [DY286018] 3. Huang L, Wang R, Xie K, et al. A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation. Breast Cancer Res Treat. 2022;191(1):51-61. [DY286018] |
| 참고사항 | For Research Use Only. |

Standard Curve of Disitamab ELISA Kit


+86-027-65523339
중국 우한시 심둔사로 666번지 C동, 우한, 430206

中文
English
한국어
日本語
Español
Français
Русский